Literature DB >> 18458945

Effects of K-201 on the calcium pump and calcium release channel of rat skeletal muscle.

Janos Almassy1, Monika Sztretye, Balazs Lukacs, Beatrix Dienes, Laszlo Szabo, Peter Szentesi, Guy Vassort, Laszlo Csernoch, Istvan Jona.   

Abstract

The benzothiazepine derivative K-201 has been suggested as a potential therapeutic agent due to its antiarrhythmogenic action. To understand how the drug alters calcium release from the sarcoplasmic reticulum (SR), we investigated its effects on the SR calcium channel and calcium pump by single channel electrophysiology, whole-cell confocal microscopy, and ATPase activity measurements on control and post-myocardial infarcted (PMI) rat skeletal muscle. In bilayers, K-201 induced two subconductance states corresponding to approximately 24% (S(1)) and approximately 13% (S(2)) of the maximum conductance. Dependence of event frequency and of time spent in S(1) and S(2) on the drug concentration was biphasic both in control and in PMI rats, with a maximum at 50 microM. At this concentration, the channel spends 26 +/- 4% and 24 +/- 4%, respectively, of the total time in these subconductance states at positive potentials, while no subconductances are observed at negative potentials. K-201 altered the frequency of elementary calcium release events: spark frequency decreased from 0.039 +/- 0.001 to 0.023 +/- 0.001 s(-1) sarcomere(-1), while the frequency of embers increased from 0.011 +/- 0.001 to 0.023 +/- 0.001 s(-1) sarcomere(-1). Embers with different amplitude levels were observed after the addition of the drug. K-201 inhibited the Ca(2+) ATPase characterized by IC(50,contr) = 119 +/- 21 muM and n (Hill,contr) = 1.84 +/- 0.48 for control and IC(50,PMI) = 122 +/- 18 microM and n (Hill,PMI) = 1.97 +/- 0.24 for PMI animals. These results suggest that although K-201 would increase the appearance of subconductance states, the overall calcium release is reduced by the drug. In addition, the effect of K-201 is identical on calcium release channels from control and PMI rats.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18458945     DOI: 10.1007/s00424-008-0504-7

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  32 in total

1.  Spark- and ember-like elementary Ca2+ release events in skinned fibres of adult mammalian skeletal muscle.

Authors:  W G Kirsch; D Uttenweiler; R H Fink
Journal:  J Physiol       Date:  2001-12-01       Impact factor: 5.182

2.  Altered elementary calcium release events and enhanced calcium release by thymol in rat skeletal muscle.

Authors:  Péter Szentesi; Henrietta Szappanos; Csaba Szegedi; Monika Gönczi; István Jona; Julianna Cseri; László Kovács; László Csernoch
Journal:  Biophys J       Date:  2004-03       Impact factor: 4.033

Review 3.  Remodeled cardiac calcium channels.

Authors:  Geoffrey S Pitt; Wen Dun; Penelope A Boyden
Journal:  J Mol Cell Cardiol       Date:  2006-08-08       Impact factor: 5.000

Review 4.  Novel targets for treating heart and muscle disease: stabilizing ryanodine receptors and preventing intracellular calcium leak.

Authors:  Stephan E Lehnart
Journal:  Curr Opin Pharmacol       Date:  2007-02-15       Impact factor: 5.547

5.  Inhibition of annexin V-dependent Ca2+ movement in large unilamellar vesicles by K201, a new 1,4-benzothiazepine derivative.

Authors:  N Kaneko; R Matsuda; M Toda; K Shimamoto
Journal:  Biochim Biophys Acta       Date:  1997-11-13

6.  Effect of a novel cardioprotective agent, JTV-519, on metabolism, contraction and relaxation in the ischemia-reperfused rabbit heart.

Authors:  H Kawabata; T Ryomoto; K Ishikawa
Journal:  Jpn Circ J       Date:  2000-10

7.  A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure.

Authors:  Masateru Kohno; Masafumi Yano; Shigeki Kobayashi; Masahiro Doi; Tetsuro Oda; Takahiro Tokuhisa; Shinichi Okuda; Tomoko Ohkusa; Michihiro Kohno; Masunori Matsuzaki
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-11-14       Impact factor: 4.733

8.  Ca2+ sparks and embers of mammalian muscle. Properties of the sources.

Authors:  J Zhou; G Brum; A Gonzalez; B S Launikonis; M D Stern; E Rios
Journal:  J Gen Physiol       Date:  2003-07       Impact factor: 4.086

9.  Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2.

Authors:  Xander H T Wehrens; Stephan E Lehnart; Steven R Reiken; Shi-Xian Deng; John A Vest; Daniel Cervantes; James Coromilas; Donald W Landry; Andrew R Marks
Journal:  Science       Date:  2004-04-09       Impact factor: 47.728

10.  Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model.

Authors:  Koichiro Kumagai; Hideko Nakashima; Naoki Gondo; Keijiro Saku
Journal:  J Cardiovasc Electrophysiol       Date:  2003-08
View more
  4 in total

1.  Charged surface area of maurocalcine determines its interaction with the skeletal ryanodine receptor.

Authors:  Balázs Lukács; Mónika Sztretye; János Almássy; Sándor Sárközi; Beatrix Dienes; Kamel Mabrouk; Cecilia Simut; László Szabó; Péter Szentesi; Michel De Waard; Michel Ronjat; István Jóna; László Csernoch
Journal:  Biophys J       Date:  2008-07-11       Impact factor: 4.033

2.  Trisk 32 regulates IP(3) receptors in rat skeletal myoblasts.

Authors:  Tamás Oláh; János Fodor; Sarah Oddoux; Olga Ruzsnavszky; Isabelle Marty; László Csernoch
Journal:  Pflugers Arch       Date:  2011-08-03       Impact factor: 3.657

Review 3.  Role of ryanodine receptor subtypes in initiation and formation of calcium sparks in arterial smooth muscle: comparison with striated muscle.

Authors:  Kirill Essin; Maik Gollasch
Journal:  J Biomed Biotechnol       Date:  2009-12-08

4.  Designing calcium release channel inhibitors with enhanced electron donor properties: stabilizing the closed state of ryanodine receptor type 1.

Authors:  Yanping Ye; Daniel Yaeger; Laura J Owen; Jorge O Escobedo; Jialu Wang; Jeffrey D Singer; Robert M Strongin; Jonathan J Abramson
Journal:  Mol Pharmacol       Date:  2011-10-11       Impact factor: 4.436

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.